Amgen (NASDAQ:AMGN) Now Covered by Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group started coverage on shares of Amgen (NASDAQ:AMGN) in a research note issued on Tuesday. The brokerage set a “hold” rating and a $350.00 price target on the medical research company’s stock. Jefferies Financial Group’s target price would suggest a potential downside of 7.15% from the company’s current price.

Other analysts also recently issued research reports about the company. Scotiabank began coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Argus boosted their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Guggenheim raised their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Finally, Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $354.00.

Amgen Stock Up 2.0%

Shares of NASDAQ:AMGN opened at $376.97 on Tuesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. Amgen has a 1 year low of $261.43 and a 1 year high of $391.29. The business’s 50-day moving average is $354.21 and its 200-day moving average is $323.38.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen will post 20.62 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMGN. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $26,000. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth $33,000. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.